LifeVantage (LFVN) AI Stock Analysis

• Market Cap: $164.91M
• Dividend Yield: 1.22%
• Average Volume (3M): 103.73K
• Price to Earnings (P/E): 19.4
• Beta (1Y): -0.12
• Revenue Growth: 8.22%
• EPS Growth: 159.71%
• Country: US
• Employees: 222
• Sector: Consumer Defensive
• Sector Strength: 48
• Industry: Packaged Foods
• EPS (TTM): 0.26
• Shares Outstanding: 12,588,183
• 10 Day Avg. Volume: 111,259
• 30 Day Avg. Volume: 103,728
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 0.83
• Enterprise Value/Gross Profit: 1.03
• Enterprise Value/Ebitda: 11.36
• 1Y Price Target: $14.50
• Price Target Upside: 7.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: $14.50 ▲(7.01% Upside)

LifeVantage's overall stock score of 74 reflects strong financial performance, particularly in profitability and cash flow generation, and positive earnings call outcomes, with projected revenue growth and successful product launches. Technical analysis presents mixed signals, while valuation is fair. The company's ability to manage international challenges and improve operational efficiency will be crucial for sustaining growth.

LifeVantage Business Overview & Revenue Model

Company Description

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

How the Company Makes Money

LifeVantage makes money primarily through direct sales and a multi-level marketing (MLM) business model. Revenue is generated from the sale of its nutraceutical and personal care products to both independent distributors and retail customers. The company's distributors purchase products at a wholesale price and sell them at retail prices, earning commissions based on their sales volume. Additionally, distributors are incentivized to recruit new members into their sales network, which can further drive sales and increase commission opportunities. LifeVantage also leverages various partnerships and collaborations to expand its market reach and enhance product distribution, contributing to its revenue streams.

LifeVantage Financial Statement Overview

Summary

LifeVantage demonstrates a strong financial position with excellent profitability metrics and robust cash flow generation. The company exhibits a healthy gross profit margin of 80.3% and a net profit margin improvement to 4.1%, indicating effective cost management and profitability. The balance sheet is stable with an equity ratio of 44.0% and a conservative debt-to-equity ratio of 0.36. Cash flow is strong, with a free cash flow growth rate of 20.3%. While revenue growth is moderate, operational efficiency improvements remain a priority.

Income Statement

LifeVantage's income statement shows a healthy gross profit margin of 80.3% for TTM, indicating efficient cost management. The net profit margin improved to 4.1% from the previous year's 1.5%, reflecting enhanced profitability. Revenue growth is moderate with a TTM increase to $222.3M from $213.4M, a 4.2% growth rate compared to the previous year, highlighting a positive growth trend. However, EBIT and EBITDA margins at 5.8% and 7.3% respectively, though improved, suggest room for operational efficiency gains.

Balance Sheet

The balance sheet reveals a solid equity base with an equity ratio of 44.0% in TTM, suggesting a stable financial structure. The debt-to-equity ratio is at a manageable 0.36, indicating conservative leverage. Return on equity is 26.9% for TTM, showing strong returns for shareholders. However, total assets have seen modest growth, and maintaining asset efficiency is crucial for future expansion.

Cash Flow

Cash flow analysis indicates robust free cash flow generation in TTM, with a notable free cash flow growth rate of 20.3%. The operating cash flow to net income ratio is 1.47, demonstrating strong cash generation relative to accounting profits. The free cash flow to net income ratio is impressive at 1.31, underscoring the company's ability to convert profits into cash effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	222.35M	200.16M	213.40M	206.36M	220.18M	232.91M
Gross Profit	178.53M	158.72M	170.01M	168.26M	181.99M	194.95M
EBITDA	16.18M	7.93M	4.26M	9.75M	23.07M	19.88M
Net Income	9.15M	2.94M	2.54M	3.12M	12.89M	11.55M
Balance Sheet
Total Assets	77.24M	60.30M	66.12M	70.71M	78.73M	58.88M
Cash, Cash Equivalents and Short-Term Investments	22.47M	16.89M	21.61M	20.19M	23.17M	22.14M
Total Debt	12.36M	13.61M	13.09M	15.76M	18.18M	1.18M
Total Liabilities	43.23M	34.31M	31.47M	39.19M	41.92M	25.62M
Stockholders Equity	34.01M	25.99M	34.65M	31.52M	36.81M	33.25M
Cash Flow
Free Cash Flow	11.98M	9.95M	3.76M	6.43M	12.53M	15.64M
Operating Cash Flow	13.43M	12.20M	6.83M	7.96M	16.27M	18.33M
Investing Cash Flow	-1.45M	-2.25M	-3.06M	-1.53M	-3.73M	-2.68M
Financing Cash Flow	-7.10M	-14.42M	-2.36M	-8.95M	-11.45M	-12.42M

LifeVantage Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Positive. The current price of 13.55 is above the 20-day moving average (MA) of 13.31, above the 50-day MA of 13.11, and below the 200-day MA of 15.10, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.11 is Neutral, neither overbought nor oversold. The STOCH value of 57.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFVN.

LifeVantage Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$297.16M	22.59	9.15%	―	4.33%	-6.33%
LFVN	74 Outperform	$164.91M	19.41	30.11%	1.22%	8.22%	159.71%
SENEA	72 Outperform	$780.60M	18.16	7.04%	―	7.30%	-13.73%
USNA	70 Outperform	$583.05M	17.70	6.54%	―	2.75%	-37.25%
HLF	63 Neutral	$1.01B	3.08	-31.74%	―	-2.25%	288.79%
Sector *	63 Neutral	$20.41B	14.67	-2.94%	3.10%	2.04%	-6.12%
HAIN	46 Neutral	$162.46M	―	-31.83%	―	-8.50%	-186.18%